莱茵生物(002166) - 2022 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2022 reached ¥337,136,268.94, an increase of 29.97% year-over-year, and year-to-date revenue was ¥978,883,646.66, up 37.44% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2022 was ¥42,480,485.91, representing a 51.87% increase year-over-year, with a year-to-date net profit of ¥175,812,920.45, up 100.71%[3] - Basic earnings per share for Q3 2022 was ¥0.07, a 40.00% increase, while diluted earnings per share also stood at ¥0.07, reflecting the same growth[3] - The company's total revenue for the first three quarters of 2022 reached CNY 978.88 million, a 37.44% increase compared to CNY 712.25 million in the same period of 2021, driven by strong demand in the plant extraction market[19] - Net profit attributable to shareholders of the parent company was CNY 175,812,920.45, up 100.5% from CNY 87,597,659.59 year-on-year[35] - Operating profit for the period was CNY 245,930,427.56, representing a significant increase from CNY 111,320,546.71 in the previous year[35] Assets and Equity - Total assets as of September 30, 2022, amounted to ¥4,451,645,750.27, a 36.60% increase from the previous year-end[4] - Shareholders' equity reached ¥3,064,802,739.15, marking a significant increase of 64.01% compared to the previous year-end[4] - The company's total equity attributable to shareholders of the parent company increased to CNY 3,064,802,739.15 from CNY 1,868,651,254.39[34] - Total assets increased to RMB 4,451,645,750.27 as of September 30, 2022, up from RMB 3,259,000,827.99 at the beginning of the year[32] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥133,200,628.82, showing a decrease of 25.55% compared to the previous year[3] - The company reported a net cash flow from financing activities of CNY 1.04 billion, a remarkable increase of 882.33% from a net outflow of CNY 132.60 million in the same period last year, primarily due to funds raised from a private placement[15] - Cash inflow from operating activities amounted to CNY 1,059,595,375.87, an increase from CNY 800,589,857.40 in the previous year[36] - The cash inflow from financing activities reached ¥1,567,806,472.25, significantly higher than ¥448,316,262.17 in Q3 2021, leading to a net cash flow from financing activities of ¥1,037,369,130.36[37] Investments and Expenditures - The company plans to invest up to RMB 730,000,000 in its wholly-owned subsidiary for the construction of a specialized stevia extraction factory, with RMB 50,000,000 allocated to registered capital[28] - The company’s investment activities resulted in a net cash outflow of CNY 267.11 million, a 288.04% increase in outflow compared to the previous year, mainly due to participation in Guilin Bank's share placement[15] - The total cash outflow from investing activities was ¥289,146,987.74, compared to ¥144,370,044.49 in the previous year, resulting in a net cash flow from investing activities of -¥267,109,083.21[37] Research and Development - Research and development expenses increased by 40.31% to CNY 35.37 million from CNY 25.21 million, reflecting higher investment in R&D during the reporting period[19] - Research and development expenses rose to CNY 35,365,974.87, up from CNY 25,206,415.86 in the previous year, indicating a focus on innovation[34] Other Financial Metrics - The company’s net asset return rate was 1.78% for Q3 2022, reflecting a slight increase of 0.25% compared to the previous year[3] - The company’s weighted average return on equity rose to 8.40%, an increase of 3.59% compared to the previous year[20] - The company reported a significant increase in other comprehensive income, totaling CNY 59,228,633.19, compared to a loss of CNY 3,380,440.22 in the same quarter last year[35] Legal and Compliance - The company faced a lawsuit resulting in a potential liability of approximately USD 1.33 million, impacting net profit by about RMB 17.83 million[30] - The report for Q3 2022 was not audited, which may affect the perception of financial reliability[39] Cash and Cash Equivalents - The company reported a cash balance of RMB 994,164,870.52 as of September 30, 2022, compared to RMB 97,411,157.55 at the beginning of the year[31] - The net cash and cash equivalents increased by 4,035.99% to CNY 905.09 million, primarily due to the funds received from the private placement[15] - The total cash and cash equivalents at the end of Q3 2022 amounted to ¥968,033,105.23, up from ¥119,043,168.43 at the end of Q3 2021[37]